NOVOZYMES, GREAT GREEN PLAY BUT WAIT (REDUCE; -9% DOWNSIDE)
20/11/20 -"Novozymes (Reduce, Denmark) is a classic example of a ‘good company at an unattractive price’. We were cautiously optimistic on this Denmark-based enzyme market leader (48% share) when we teased ..."
Pages
51
Language
English
Published on
20/11/20
You may also be interested by these reports :
27/01/26
Critical USA size increase with value-accretive capacity acquisition
20/01/26
Virbac ended 2025 on a strong note, with sales growth (at CERS) exceeding the management’s guidance that was upgraded only in October 2025. The ...
15/01/26
In late-2024, when we last teased the story of DiaSorin (BUY; Italy), a family-owned in-vitro diagnostic company specialising in immunodiagnostics ...
09/01/26
Hikma, over the years, has struggled to create shareholder wealth, perhaps because of its inability (until now) to develop biosimilars on its own. ...